Preventing Donepezil-Induced Adverse Effects Through N-acetylcysteine Co-Administration
Journal of Alzheimer's Disease · 08.10.2024 · 101 (4) · 1281-1292
DOI: 10.3233/jad-240709 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer's Disease, erschienen am 08.10.2024. Verfasst von Jiae Park und 5 weiteren Autor:innen. Beteiligte Einrichtung: DR. NOAH Biotech Inc., Suwon, Republic of Korea. Hauptthemen laut MEDLINE: Donepezil, Acetylcysteine, Rats, Sprague-Dawley, Cholinesterase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
Background
Drug-induced adverse symptoms affect patients’ quality of life (QoL) during treatment. Understanding the underlying mechanisms of drug-induced adverse effects could help prevent them. As current drugs have limited effects in halting the progress of Alzheimer’s disease (AD), patients are required to take these drugs over a long period. The main obstacles to long-term compliance are drug-elicited side effects that deteriorate patient QoL.
Objective
Donepezil, the most popular acetylcholinesterase inhibitor (AChEI) drug for AD, induces various side effects, especially at high doses. This study aimed to identify a drug that can attenuate the side effects of donepezil and investigate the underlying mechanisms.
Methods
Five-week-old Sprague-Dawley rats received daily oral donepezil and N-acetylcysteine (NAC) for four weeks. General symptoms following administration were monitored daily to address drug-related adverse effects. Cytosolic calcium influx and generation of reactive oxygen species (ROS) after drug treatment were measured in vitro using C2C12 myotubes.
Results
High-dose donepezil induced numerous adverse symptoms in male and female rats, which were markedly attenuated by co-treatment with NAC. NAC significantly reduced both acute and chronic muscle-related symptoms caused by donepezil. Additionally, in vitro studies showed that high-dose donepezil increased ROS and intracellular calcium ([Ca2+]i) levels in muscle cells, contributing to these adverse effects. NAC co-treatment dramatically reduced ROS and [Ca2+]i levels in muscle cells.
Conclusions
Combined treatment with NAC effectively diminishes the adverse effects elicited by donepezil by regulating ROS and [Ca2+]i levels in the skeletal muscle, which could contribute to improving donepezil treatment in patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- DR. NOAH Biotech Inc., Suwon, Republic of Korea.
Zitieren
APA
Park, J., Oh, J. P., Ku, K., Jin, Y., Kim, E. J., & Lee, J. H. (2024). Preventing Donepezil-Induced Adverse Effects Through N-acetylcysteine Co-Administration. Journal of Alzheimer's Disease, 101(4), 1281-1292. https://doi.org/10.3233/jad-240709
Vancouver
Park J, Oh JP, Ku K, Jin Y, Kim EJ, Lee JH. Preventing Donepezil-Induced Adverse Effects Through N-acetylcysteine Co-Administration. Journal of Alzheimer's Disease. 2024;101(4):1281-1292. doi:10.3233/jad-240709
BibTeX
@article{Park2024,
author = {Park, Jiae and Oh, Jung-Pyo and Ku, Kyojin and Jin, Yeonsun and Kim, Eun Jung and Lee, Ji-Hyun},
title = {Preventing Donepezil-Induced Adverse Effects Through N-acetylcysteine Co-Administration},
journal = {Journal of Alzheimer's Disease},
year = {2024},
volume = {101},
number = {4},
pages = {1281--1292},
doi = {10.3233/jad-240709}
}
EUVIMED